HTRS2025.P2.78 REAL-WORLD UTILIZATION of EPTACOG BETA* in the USA

20250 citationsJournal Articlegold Open Access

Authors

Robert F. Sidonio · Bleeding & Clotting Disorders Institute

Ahmad Al‐Huniti · Mayo Clinic

Vinod Balasa · Center for Cancer and Blood Disorders

Andrea Dvorak · SUNY Upstate Medical University

Doris Quon · Orthopaedic Institute for Children

Michael H. White · Children's Healthcare of Atlanta

Andreana Robertson

Abstract

Background: Eptacog beta is approved in the USA for the treatment of bleeding events (BEs) in adults and adolescents with hemophilia A or B with inhibitors (HABI). However, few data have been published on its real-world utilization in the USA.

Topics & Keywords

Hemophilia Treatment and Research Coagulation, Bradykinin, Polyphosphates, and Angioedema Blood Coagulation and Thrombosis Mechanisms

Publication Details

Published in: Research and Practice in Thrombosis and Haemostasis

Volume 9, pp. 103097-103097

DOI: 10.1016/j.rpth.2025.103097

Field-Weighted Citation Impact: 0.00

Command Palette

HTRS2025.P2.78 REAL-WORLD UTILIZATION of EPTACOG BETA* in the USA

Authors

Abstract

Topics & Keywords

Publication Details